Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
2107 articles with Gilead Sciences, Inc.
-
Gilead Sciences, Inc. to Present at the Sanford C. Bernstein 26th Annual Strategic Decisions Conference on Thursday, June 3
5/28/2010
-
Gilead Sciences, Inc. Board Approves $5 Billion Buyback
5/11/2010
-
Gilead Sciences, Inc. to Present at the Bank of America Merrill Lynch 2010 Healthcare Conference on Thursday, May 13
5/7/2010
-
Gilead Sciences, Inc. Finalizes Selection of Bioequivalent Formulation for the Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals Ltd's TMC278
4/27/2010
-
Gilead Sciences, Inc. Announces Record First Quarter 2010 Financial Results
4/21/2010
-
Gilead Sciences, Inc. Stops Hepatitis Drug Trial for Patient Safety
4/20/2010
-
Gilead Sciences, Inc. Provides Update on Development of Fixed-Dose Regimen of Truvada(R) and Tibotec Pharmaceuticals Ltd's TMC278
4/20/2010
-
Gilead Sciences, Inc. Drug GS-9450 Effective Against Liver Disease In Phase II Study
4/16/2010
-
Gilead Sciences, Inc. to Release First Quarter 2010 Financial Results on Tuesday, April 20, 2010
4/14/2010
-
Gilead Sciences, Inc. Initiates Phase III Clinical Program Evaluating Single-Tablet, Once-Daily “Quad” Regimen for HIV
4/13/2010
-
U.S. FDA Warns Gilead Sciences, Inc., Biogen Idec, Inc. (Massachusetts) Over Drug Promotions
4/8/2010
-
Gilead Sciences, Inc. to Present at the Barclays Capital 2010 Global Healthcare Conference on Wednesday, March 24
3/18/2010
-
Gilead Sciences, Inc. to Present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11
3/5/2010
-
FDA Approves Gilead Sciences, Inc.'s (JOBS) Cayston(R) for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients with Pseudomonas Aeruginosa
2/23/2010
-
Gilead Sciences, Inc.'s Single-Tablet "Quad" Regimen for HIV Achieves a High Rate of Virologic Suppression in Phase II Study
2/18/2010
-
Gilead Sciences, Inc. to Present at the 12th Annual Biotechnology Industry Organization (BIO) CEO Investor Conference on Tuesday, February 9
2/3/2010
-
Per Wold-Olsen Joins Gilead Sciences, Inc.'s Board of Directors
1/29/2010
-
Gilead Sciences, Inc. Announces Share Repurchase Program
1/29/2010
-
Gilead Sciences, Inc. Announces Record Fourth Quarter and Full Year 2009 Financial Results
1/27/2010
-
Gilead Sciences, Inc. (JOBS) Profit Beats Street, Shares Up
1/27/2010